Preliminary efficacy results have been announced for a vaccine from Moderna in the US. Although based on a small amount of data, the indication is that this vaccine is even more effective than the Pfizer BioNtech vaccine, which was high-lighted last week. Trials of both these vaccines have shown that they are equally effective for people in older age groups. The Oxford University Astrazeneca group has just published some peer-reviewed research in the Lancet, which shows that their vaccine also produces a strong immune response in older adults.
Vaccine Distribution and Transport
Transport and distribution of the vaccines is likely to pose some challenging logistical problems. The Pfizer and Moderna vaccines need to be transported and stored at very low temperatures – well below those experienced in most commercial settings. The Oxford vaccine can be stored at normal clinical refrigeration temperatures and if it proves effective will be easier to distribute, particularly in less well-developed countries.